Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 4 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Propranolol × 30 days × Clear all
NCT06120140 2026-06-05

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05741164 2026-06-04

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Emory University

Phase 2 Recruiting
37 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02104011 2026-05-19

STBETA

University Hospital, Bordeaux

Phase 2 Completed
2 enrolled

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡